To amend title XVIII of the Social Security Act to provide for certain reforms under the Medicare Advantage program, and for other purposes.

HR8375, titled 'To amend title XVIII of the Social Security Act to provide for certain reforms under the Medicare Advantage program, and for other purposes,' was introduced in the House on April 20, 2026, by Rep. Joyce (R-PA). It has since been referred to the Committee on Ways and Means and the Committee on Energy and Commerce. On April 27, 2026, the sponsor made introductory remarks on the measure, indicating active engagement with the bill. The bill's status is 'Active' and it is in the early stages of the legislative process. This bill does not specify any direct funding amounts; rather, it aims to reform the Medicare Advantage program. The mechanism would involve changes to the existing regulatory framework and potentially the reimbursement models for Medicare Advantage plans. As an authorization bill, it sets policy direction, and any financial implications would stem from those policy changes, not direct appropriations within this bill itself. The specific nature of the reforms is not detailed in the provided information, but any changes would directly affect the operational and financial models of companies administering Medicare Advantage plans. Structural winners and losers will depend on the specific reforms proposed. Companies with significant exposure to the Medicare Advantage market, such as UnitedHealth Group ($UNH), CVS Health ($CVS) through Aetna, Humana ($HUM), Centene ($CNC), and Molina Healthcare ($MOH), are directly impacted. The direction of impact (bullish or bearish) cannot be determined without the specific text of the proposed reforms. For example, reforms that increase plan flexibility or reduce administrative burdens could be bullish, while those that reduce reimbursement rates or increase regulatory compliance costs could be bearish. Given the early stage of the bill, no specific market movements can be attributed to this event. The bill is currently in committee, and further legislative steps, including committee hearings, markups, and potential floor votes, would be required for it to advance. No recent presidential actions are directly relevant to the Medicare Advantage program or the healthcare sector in a way that amplifies or conflicts with this specific bill. The presidential memoranda provided relate to domestic petroleum production and defense operations, which are distinct from healthcare policy.